Compare Hormel Foods Corp (HRL) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Novo Nordisk A/S — how do they compare? Hormel Foods Corp trades at $19.29 (market cap $10.69B), while Novo Nordisk A/S trades at $38.49 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 15.5× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and Novo Nordisk A/S for 116 Days on average.
| HRL | NVO | |
|---|---|---|
Market Cap | $10.69B | $165.31B |
Volume | 10,041,387 | 11,432,838 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $63.98 |
52-Week Low | $19.42 | $35.29 |
Typical Hold Time | 99 Days | 116 Days |
Enterprise Value | $12.67B | $179.56B |
Dividend Yield | 6.02% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.23, down 1.64% on the day, with a bearish technical outlook despite recent earnings beats. The company maintains a P/E of 31.32 and P/S of 0.88, with net income margin at 2.82%. Recent $1.06B Brakebush acquisition aims to expand foodservice presence, while dividend consistency remains a key investor focus with 60 consecutive years of increases.
Outlook remains cautious with mixed analyst sentiment (20% buy, 57% hold) and a $24.25 consensus target offering 26% upside. Risks include margin pressure, acquisition integration challenges, and declining dividend growth rates. The stock presents value potential but requires monitoring of operational execution amid competitive pressures.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
